Adding rolapitant improves prevention of chemo-induced nausea, vomiting
the ONA take:
Rolapitant in combination with a 5-HT3 receptor antagonist and dexamethasone is well-tolerated and demonstrates superiority over active control for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the at-risk period following the administration of highly emetogenic cisplatin-based chemotherapy, a new study published online ahead of print in The Lancet Oncology has shown.
Two double-blind, active-controlled, phase 3 trials were conducted to assess rolapitant, a neurokinin-1 receptor antagonist, for the prevention of CINV in patients with cancer in the 120 hours after administration of cisplatin-based chemotherapy.
Patients were randomly assigned to receive either oral rolapitant 180 mg or placebo 1 to 2 hours before cisplatin in conjunction with granisetron and dexamethasone. Results showed that a significantly higher proportion of patients in the rolapitant arms achieved completes responses during the delayed phase than did patients who received placebo.
In regard to safety, no serious treatment-emergent adverse events were related to rolapitant treatment.
The findings suggest that adding rolapitant to granisetron and dexamethasone is superior to granisetron and dexamethasone alone for the prevention of CINV during the delayed phase after receiving cisplatin-based chemotherapy.
Rolapitant demonstrates superiority over active control for the prevention of chemotherapy-induced nausea and vomiting.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|